Home > Drug Updates & Recalls > FDA Side Effect Updates > FDA SIDE EFFECTS UPDATE: Testosterone Drugs and High Blood Pressure Risk

FDA SIDE EFFECTS UPDATE: Testosterone Drugs and High Blood Pressure Risk

Safety updates sourced directly from the FDA's Drug Safety Database, presented in clear and accessible language

Katie Rowley

October 1, 2025

0 Comments

republish

Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your medications. In this installment, we’re highlighting safety updates concerning Androgel, Aveed, Azmiro, Jatenzo, Kyzatrex, Natesto, Testim, Tlando, Vogelxo, and Xyosted.

Side Effect Update for Testosterone Drugs

The medications included in this update are approved for adult males with conditions associated with a deficiency or absence of the male hormone testosterone. These conditions include primary hypogonadism, which occurs when the testes do not function properly, and secondary hypogonadism, which occurs when the problem originates in the pituitary gland. Symptoms of low testosterone, or “Low-T,” include reduced sex drive, erectile dysfunction, fatigue, and mood changes.

Testosterone-containing drugs that treat Low-T include topical gels, transdermal patches, buccal system (applied to upper gum or inner cheek), tablets, capsules and injections. Testosterone is a Class III controlled drug, due to its potential for abuse.

How to Read This Report

This report is prepared using the most recent information posted in the SrLC database. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.

Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.

These safety label updates were made in response to an FDA assessment of a clinical trial study called the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE). The study showed that the use of testosterone drugs did not increase the risk of death from cardiovascular causes more than placebo. The warning about major cardiovascular risks, which had been included on the labels since 2015, was removed in this update.

However, the TRAVERSE study also showed that participants taking testosterone experienced an increased incidence of venous thromboembolism (VTE), including deep vein thrombosis (DVT, a type of vein blockage caused by a blood clot in the leg) and pulmonary embolism (PE, a blockage caused by a blood clot in the lung). Warnings about VTE have been included on the labels since 2014. Updated safety information regarding VTE now includes the TRAVERSE clinical trials results and a warning in the patient counseling section.

Because the TRAVERSE study and additional ambulatory blood pressure (ABPM) studies showed an increased risk of developing high blood pressure among users of testosterone, a new warning about the risk of developing high blood pressure was also added.

Androgel (testosterone gel) 1% for topical use and 1.62% for topical use

Initial FDA Approval: 1953 (testosterone); this formulation was approved in 2000

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.

A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.

FDA Safety Announcement: Androgel 1% FDA Safety Label Change and Revised Drug Label
Androgel 1.62% FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Aveed (testosterone undecanoate) injection, for intramuscular use

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2014

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone. This medication is administered by a healthcare professional in a healthcare setting.

Essential Extras: Aveed is available only through a restricted program called the Aveed REMS Program because of the risk of serious Pulmonary Oil Microembolism (POME) reactions and anaphylaxis during or immediately after receiving the injection. POME reactions involve the urge to cough, dyspnea, throat tightening, chest pain, dizziness, and fainting.

FDA Safety Announcement: Aveed FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Azmiro (testosterone cypionate) injection, solution for intramuscular use

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2022

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Azmiro FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Stay Informed. Sign up for our newsletters.

Independent, science-based journalism delivered directly to your inbox.

Jatenzo (testosterone undecanoate) capsules

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2019

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Jatenzo FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Kyzatrex (testosterone undecanoate) capsules, liquid filled

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2022

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Kyzatrex FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Natesto (testosterone) nasal gel

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2014

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Natesto FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Testim (testosterone gel) for topical use

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2002

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Testim FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Tlando (testosterone undecanoate) capsule, liquid filled

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2022

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Tlando FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Vogelxo (testosterone) gel, for topical use

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2014

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Vogelxo FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Xyosted (testosterone enanthate) autoinjector, subcutaneous

Initial FDA Approval: 1953 (testosterone); this formulation approved in 2018

Side Effect Update Date: July 11, 2025

Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.

FDA Safety Announcement: Xyosted FDA Safety Label Change and Revised Drug Label

The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

republish this story

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

FDA SIDE EFFECTS UPDATE: Osteoporosis Drugs and New Bone Fracture Risks

February 2, 2026

FDA SIDE EFFECTS UPDATE: Bupropion Antidepressants and the Risk of Drug-Induced Meningitis

January 8, 2026

FDA SIDE EFFECTS UPDATE: New Warnings for Stelara, Tepezza, and Other Autoimmune Drugs

DONATE:

Help fund our fight for improved medication safety and transparency by supporting our independent journalism.

Give Now

Stay Informed. Sign up for our newsletters.

Independent, science-based journalism delivered directly to your inbox.

We seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.

Our Mission

MedShadow Foundation

Our Founder

DES Action USA

WEBINARS

Learn about your medications and treatment options straight from independent experts.

WATCH

Follow Us On:

Download our App:

Article HTML

                    <!-- wp:paragraph -->
<p>Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your medications. In this installment, we’re highlighting safety updates concerning Androgel, Aveed, Azmiro,  Jatenzo, Kyzatrex, Natesto, Testim, Tlando, Vogelxo, and Xyosted.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":1} -->
<h1 class="wp-block-heading" id="h-side-effect-update-for-testosterone-drugs">Side Effect Update for Testosterone Drugs</h1>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p>The medications included in this update are approved for adult males with conditions associated with a deficiency or absence of the male hormone <a href="https://www.merriam-webster.com/dictionary/testosterone#medicalDictionary" target="_blank" rel="noreferrer noopener">testosterone</a>. These conditions include primary <a href="https://medlineplus.gov/ency/article/001195.htm" target="_blank" rel="noreferrer noopener">hypogonadism</a>, which occurs when the <a href="https://www.merriam-webster.com/dictionary/testes" target="_blank" rel="noreferrer noopener">testes</a> do not function properly, and secondary hypogonadism, which occurs when the problem originates in the <a href="https://www.merriam-webster.com/dictionary/pituitary%20gland" target="_blank" rel="noreferrer noopener">pituitary gland</a>. Symptoms of low testosterone, or “Low-T,” include reduced sex drive, erectile dysfunction, fatigue, and mood changes.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Testosterone-containing drugs that treat Low-T include topical gels, transdermal patches, buccal system (applied to upper gum or inner cheek), tablets, capsules and injections. Testosterone is a Class III controlled drug, due to its <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-changes-testosterone-labeling-regarding-risks-associated-abuse-and-dependence" target="_blank" rel="noreferrer noopener">potential for abuse</a>.</p>
<!-- /wp:paragraph -->

<!-- wp:myplugin/custom-alignment-block {"align":"right"} -->
<div class="wp-block-myplugin-custom-alignment-block alignright"><h2>How to Read This Report</h2><p>This report is prepared using the most recent information posted in the <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm" target="_blank" rel="noreferrer noopener">SrLC database</a>. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.<br><br>Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.</p></div>
<!-- /wp:myplugin/custom-alignment-block -->

<!-- wp:paragraph -->
<p>These safety label updates were made in response to an <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-class-wide-labeling-changes-testosterone-products" target="_blank" rel="noreferrer noopener">FDA assessment</a> of a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2215025" target="_blank" rel="noreferrer noopener">clinical trial study</a> called the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE). The study showed that the use of testosterone drugs did not increase the risk of death from cardiovascular causes more than placebo. The warning about major cardiovascular risks, which had been included on the labels <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022309Orig1s014ltr.pdf" target="_blank" rel="noreferrer noopener">since 2015</a>, was removed in this update.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>However, the TRAVERSE study also showed that participants taking testosterone experienced an increased incidence of <a href="https://www.nhlbi.nih.gov/health/venous-thromboembolism" target="_blank" rel="noreferrer noopener">venous thromboembolism</a> (VTE), including deep vein thrombosis (DVT, a type of vein blockage caused by a blood clot in the leg) and pulmonary embolism (PE, a blockage caused by a blood clot in the lung). Warnings about VTE have been included on the labels <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022309Orig1s012ltr.pdf" target="_blank" rel="noreferrer noopener">since 2014</a>. Updated safety information regarding VTE now includes the TRAVERSE clinical trials results and a warning in the patient counseling section.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Because the TRAVERSE study and additional ambulatory blood pressure (ABPM) studies showed an increased risk of developing high blood pressure among users of testosterone, a new warning about the risk of developing high blood pressure was also added.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-androgel-testosterone-gel-1-for-topical-use-and-1-62-for-topical-use">Androgel (testosterone gel) 1% for topical use and 1.62% for topical use</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation was approved in 2000</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description:</strong> A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>:<a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=487" target="_blank" rel="noreferrer noopener"> Androgel 1% FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021015s047lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label<br></a><a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=486" target="_blank" rel="noreferrer noopener">Androgel 1.62% FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022309s022lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-aveed-nbsp-testosterone-undecanoate-injection-for-intramuscular-use">Aveed  (testosterone undecanoate) injection, for intramuscular use</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2014</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone. This medication is administered by a healthcare professional in a healthcare setting.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: Aveed is available only through a restricted program called the <a href="https://www.aveedrems.com/s/" target="_blank" rel="noreferrer noopener">Aveed REMS Program</a> because of the risk of serious Pulmonary Oil Microembolism (POME) reactions and anaphylaxis during or immediately after receiving the injection. POME reactions involve the urge to cough, dyspnea, throat tightening, chest pain, dizziness, and fainting.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=491" target="_blank" rel="noreferrer noopener">Aveed FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022219s021lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-azmiro-testosterone-cypionate-injection-solution-for-intramuscular-use">Azmiro (testosterone cypionate) injection, solution for intramuscular use</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2022</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3153" target="_blank" rel="noreferrer noopener">Azmiro FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216318s005lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-jatenzo-testosterone-undecanoate-capsules">Jatenzo (testosterone undecanoate) capsules</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2019</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3158" target="_blank" rel="noreferrer noopener">Jatenzo FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206089s009lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-kyzatrex-testosterone-undecanoate-capsules-liquid-filled">Kyzatrex (testosterone undecanoate) capsules, liquid filled</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2022</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3159" target="_blank" rel="noreferrer noopener">Kyzatrex FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213953s005lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-natesto-testosterone-nasal-gel">Natesto (testosterone) nasal gel</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2014</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3159" target="_blank" rel="noreferrer noopener">Natesto FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205488s005lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-testim-testosterone-gel-for-topical-use">Testim (testosterone gel) for topical use</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2002</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=487" target="_blank" rel="noreferrer noopener">Testim FDA Safety Label Change</a>  and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021454s036lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-tlando-testosterone-undecanoate-capsule-liquid-filled">Tlando (testosterone undecanoate) capsule, liquid filled</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2022</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description:</strong> A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3160" target="_blank" rel="noreferrer noopener">Tlando FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208088s002lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-vogelxo-testosterone-gel-for-topical-use">Vogelxo (testosterone) gel, for topical use</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2014</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=489" target="_blank" rel="noreferrer noopener">Vogelxo FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204399s016lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

<!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-xyosted-testosterone-enanthate-autoinjector-subcutaneous">Xyosted (testosterone enanthate) autoinjector, subcutaneous</h3>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2018</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2120" target="_blank" rel="noreferrer noopener">Xyosted FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209863s020lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->

FDA SIDE EFFECTS UPDATE: Testosterone Drugs and High Blood Pressure Risk

Side Effect Update for Testosterone Drugs

How to Read This Report

Androgel (testosterone gel) 1% for topical use and 1.62% for topical use

Aveed (testosterone undecanoate) injection, for intramuscular use

Azmiro (testosterone cypionate) injection, solution for intramuscular use

Stay Informed. Sign up for our newsletters.

Jatenzo (testosterone undecanoate) capsules